1 | the patient savings card | | | | | | | 5 | 0.43% |
2 | caution in patients with | | | | | | | 4 | 0.34% |
3 | brimonidine topical gel 033 | | | | | | | 4 | 0.34% |
4 | with caution in patients | | | | | | | 4 | 0.34% |
5 | of 4 yes no | | | | | | | 4 | 0.34% |
6 | gel should be used | | | | | | | 3 | 0.26% |
7 | effects of prescription drugs | | | | | | | 3 | 0.26% |
8 | wwwfdagovmedwatch or call 1800fda1088 | | | | | | | 3 | 0.26% |
9 | by galderma laboratories lp | | | | | | | 3 | 0.26% |
10 | negative side effects of | | | | | | | 3 | 0.26% |
11 | used with caution in | | | | | | | 3 | 0.26% |
12 | be used with caution | | | | | | | 3 | 0.26% |
13 | topical gel should be | | | | | | | 3 | 0.26% |
14 | mirvaso® brimonidine topical gel | | | | | | | 3 | 0.26% |
15 | side effects of prescription | | | | | | | 3 | 0.26% |
16 | careconnect program patient savings | | | | | | | 3 | 0.26% |
17 | facial redness of rosacea | | | | | | | 3 | 0.26% |
18 | galderma careconnect program patient | | | | | | | 3 | 0.26% |
19 | rosacea in adults 18 | | | | | | | 2 | 0.17% |
20 | mirvaso topical gel out | | | | | | | 2 | 0.17% |
21 | cardiovascular disease serious adverse | | | | | | | 2 | 0.17% |
22 | following accidental ingestion of | | | | | | | 2 | 0.17% |
23 | accidental ingestion of mirvaso | | | | | | | 2 | 0.17% |
24 | ingestion of mirvaso topical | | | | | | | 2 | 0.17% |
25 | of mirvaso topical gel | | | | | | | 2 | 0.17% |
26 | mirvaso topical gel by | | | | | | | 2 | 0.17% |
27 | been reported keep mirvaso | | | | | | | 2 | 0.17% |
28 | reported keep mirvaso topical | | | | | | | 2 | 0.17% |
29 | keep mirvaso topical gel | | | | | | | 2 | 0.17% |
30 | topical gel out of | | | | | | | 2 | 0.17% |
31 | patients with severe or | | | | | | | 2 | 0.17% |
32 | gel out of reach | | | | | | | 2 | 0.17% |
33 | out of reach of | | | | | | | 2 | 0.17% |
34 | for oral ophthalmic or | | | | | | | 2 | 0.17% |
35 | oral ophthalmic or intravaginal | | | | | | | 2 | 0.17% |
36 | ophthalmic or intravaginal use | | | | | | | 2 | 0.17% |
37 | or intravaginal use you | | | | | | | 2 | 0.17% |
38 | intravaginal use you are | | | | | | | 2 | 0.17% |
39 | are encouraged to report | | | | | | | 2 | 0.17% |
40 | encouraged to report negative | | | | | | | 2 | 0.17% |